journal article·2025-01-01Open access

3D printed PGCL@PLA/10CSPL composite scaffolds loaded with fibronectin 1 for intervertebral disc degeneration treatment

Weilin Zhang, Siyuan Chen, Shengbang Huang, Zhencong Li, Zhongwei Wang, Zhiwen Dai, Jinguo Liang, Hongrui Rong, Qianqian Ouyang, Weixiong Guo, Yen Wei, Jinsong Wei

Biofabrication· Volume 17· Issue 1

Abstract

Abstract Restoration of disc height and biomechanical function is essential for intervertebral disc degeneration (IDD) treatment. Removing abnormal nucleus pulposus (NP) tissue is an important step to facilitate bony fusion during the healing process. We analyzed publicly available single-cell transcriptome data for human normal and degenerative NP to identify genes associated with NP degeneration. A novel poly(glycolide-co-caprolactone)@polylactide (PLA)-b-aniline pentamer (AP)-b-PLA/chitosan-ϵ-polylysine (PGCL@1PAP/10CSPL) scaffold with good biocompatibility and electroactivity was designed and fabricated as an implant for IDD treatment using 3D printing technology. The PGCL@1PAP/10CSPL scaffold exhibited superior hydrophilicity, mechanical properties, cytocompatibility, and antibacterial activity compared to PGCL. Fibronectin 1 (FN1), identified from single-cell transcriptome analysis, was loaded into the PGCL@1PAP/10CSPL scaffold to accelerate the abnormal NP degeneration. In vitro and in vivo experiments indicated that the PGCL@1PAP/10CSPL-FN1 scaffold enhanced osteogenic differentiation, promoted angiogenesis, and facilitated the removal of damaged disc tissue. This study introduces a novel implant system with desirable mechanical strength and unique bone-promoting and vascularizing properties for lumbar interbody fusion in IDD treatment.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Spine and Intervertebral Disc Pathology · Musculoskeletal pain and rehabilitation · Orthopaedic implants and arthroplasty

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (55)

Show source-provided references
1. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 201710.1016/S0140-6736(18)32279-7 ↗
2. Global low back pain prevalence and years lived with disability from 1990 to 2017: estimates from the global burden of disease study 201710.21037/atm.2020.02.175 ↗
4. Aging, cell senescence, the pathogenesis and targeted therapies of intervertebral disc degeneration10.3389/fphar.2023.1172920 ↗
5. A brief review of the degenerative intervertebral disc disease10.5455/medarh.2019.73.421-424 ↗
6. Effects of modic type 1 changes in the vertebrae on low back pain10.1016/j.wneu.2018.09.132 ↗
7. Influence of age, BMI, gender and lumbar level on T1ρ magnetic resonance imaging of lumbar discs in healthy asymptomatic adults10.1055/s-0043-115898 ↗
8. Age-related changes in the extracellular matrix of nucleus pulposus and anulus fibrosus of human intervertebral disc10.1097/BRS.0b013e31818e5ddd ↗
9. Osteoarthritis and intervertebral disc degeneration: quite different, quite similar10.1002/jsp2.1033 ↗
10. Diversity of intervertebral disc cells: phenotype and function10.1111/j.1469-7580.2012.01521.x ↗
11. PTEN promotes intervertebral disc degeneration by regulating nucleus pulposus cell behaviors10.1002/cbin.11258 ↗
12. Cellular senescence in intervertebral disc aging and degeneration10.1007/s40610-018-0108-8 ↗
13. Molecular mechanisms of biological aging in intervertebral discs10.1002/jor.23195 ↗
14. Current perspectives on nucleus pulposus fibrosis in disc degeneration and repair10.3390/ijms23126612 ↗
15. Treatment of intervertebral disc degeneration10.1111/os.13254 ↗
16. Metformin facilitates mesenchymal stem cell-derived extracellular nanovesicles release and optimizes therapeutic efficacy in intervertebral disc degeneration10.1016/j.biomaterials.2021.120850 ↗
17. Genetic therapy for intervertebral disc degeneration10.3390/ijms22041579 ↗
18. Stem cells and exosomes: new therapies for intervertebral disc degeneration10.3390/cells10092241 ↗
19. Biomaterials and cell-based regenerative therapies for intervertebral disc degeneration with a focus on biological and biomechanical functional repair: targeting treatments for disc herniation10.3390/cells11040602 ↗
20. Biomaterials for intervertebral disc regeneration and repair10.1016/j.biomaterials.2017.03.013 ↗
21. Multiple nano-drug delivery systems for intervertebral disc degeneration: current status and future perspectives10.1016/j.bioactmat.2022.11.006 ↗
22. 3D printed PCL/GelMA biphasic scaffold boosts cartilage regeneration using co-culture of mesenchymal stem cells and chondrocytes: in vivo study10.1016/j.matdes.2021.110065 ↗
23. Development of GelMA/PCL and dECM/PCL resins for 3D printing of acellular in vitro tissue scaffolds by stereolithography10.1016/j.msec.2020.110958 ↗
24. Biomimetic 3D printed PCL/TCP/GelMA scaffolds with improved osteogenesis and angiogenesis for non-load bearing applications10.1016/j.mtla.2022.101339 ↗
25. The development of bioresorbable composite polymeric implants with high mechanical strength10.1038/nmat5016 ↗
26. Synergistically promoting bone regeneration by icariin-incorporated porous microcarriers and decellularized extracellular matrix derived from bone marrow mesenchymal stem cells10.3389/fbioe.2022.824025 ↗
27. Effects of polymer molecular weight on relative oral bioavailability of curcumin10.2147/IJN.S32630 ↗
28. Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture10.1021/ar900035f ↗
29. In vitro generated extracellular matrix and fluid shear stress synergistically enhance 3D osteoblastic differentiation10.1073/pnas.0505661103 ↗
30. Synthesis and characterization of electroactive and biodegradable ABA block copolymer of polylactide and aniline pentamer10.1016/j.biomaterials.2006.12.007 ↗
31. In situ self-assembly chitosan/ϵ-polylysine bionanocomposite film with enhanced antimicrobial properties for food packaging10.1016/j.ijbiomac.2019.03.133 ↗
32. The significance of removing ruptured intervertebral discs for interbody fusion in treating thoracic or lumbar type B and C spinal injuries through a one-stage posterior approach10.1371/journal.pone.0097275 ↗
33. Single-cell transcriptome profiling reveals multicellular ecosystem of nucleus pulposus during degeneration progression10.1002/advs.202103631 ↗
34. Single-cell RNA-seq analysis of cells from degenerating and non-degenerating intervertebral discs from the same individual reveals new biomarkers for intervertebral disc degeneration10.3390/ijms23073993 ↗
35. Development of antibacterial ϵ-polylysine/chitosan hybrid films and the effect on citrus10.1016/j.ijbiomac.2018.07.074 ↗
36. Role of miR-155 in the regulation of MMP-16 expression in intervertebral disc degeneration10.1002/jor.23313 ↗
37. Clinical and radiographic outcomes of posterolateral lumbar spine fusion in humans using recombinant human bone morphogenetic protein-2: an average five-year follow-up study10.1007/s00264-008-0600-5 ↗
38. Full-endoscopic lumbar interbody fusion for treating lumbar disc degeneration involving disc height loss: technical report10.3390/medicina56090478 ↗
39. Intervertebral disc diseases PART 2: a review of the current diagnostic and treatment strategies for intervertebral disc disease10.3390/ijms21062135 ↗
40. Guidelines for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 1: introduction and methodology10.3171/spi.2005.2.6.0637 ↗
41. Effectiveness and safety of recombinant human bone morphogenetic protein-2 for adults with lumbar spine pseudarthrosis following spinal fusion surgery: a systematic review10.1302/2046-3758.54.2000418 ↗
42. Treatment of lumbar instability: transforaminal lumbar interbody fusion10.1053/j.semss.2005.10.005 ↗
43. Inhibitory effects of human primary intervertebral disc cells on human primary osteoblasts in a co-culture system10.3390/ijms19041195 ↗
44. Applications of chitin and chitosan nanofibers in bone regenerative engineering10.1016/j.carbpol.2019.115658 ↗
45. Chitosan derivatives and their application in biomedicine10.3390/ijms21020487 ↗
46. Structure, stability, rheology, and texture properties of ϵ-polylysine-whey protein complexes10.3168/jds.2021-21219 ↗
47. Antimicrobial biodegradable food packaging based on chitosan and metal/metal-oxide bio-nanocomposites: a review10.3390/polym13162790 ↗
48. Antimicrobial packaging based on ɛ-polylysine bioactive film for the control of mycotoxigenic fungi in vitro and in bread10.1111/jfpp.13370 ↗
49. Implant survival after deep infection of an instrumented spinal fusion10.1302/0301-620X.95B8.30784 ↗
50. Chitosomes-in-chitosan hydrogel for acute skin injuries: prevention and infection control10.3390/md19050269 ↗
51. Extracellular matrix and integrin composition of the normal bladder wall10.1007/BF00182062 ↗
52. Fibronectin 1 is a potential biomarker for radioresistance in head and neck squamous cell carcinoma10.4161/cbt.10.12.13432 ↗
53. Fibronectin-1 expression is increased in aggressive thyroid cancer and favors the migration and invasion of cancer cells10.1016/j.mce.2016.05.007 ↗
54. Silence of fibronectin 1 increases cisplatin sensitivity of non-small cell lung cancer cell line10.1016/j.bbrc.2016.05.081 ↗
55. Fibronectin in cancer: friend or foe10.3390/cells9010027 ↗